Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Medical Device Revenue Up, But Cypher Sales Are Still A Drag

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's device revenue growth is still hindered by declining sales of the Cypher sirolimus-eluting coronary stent, the company reported during its first-quarter earnings call April 17

You may also be interested in...



Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years

Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study

Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years

Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study

New Data Is Likely To Add Fuel To The Drug-Eluting-Stent Debate

New trial data presented at the American College of Cardiology annual meeting could be another obstacle to drug-eluting-stent manufacturers' efforts to reverse a year-long sales slump

Related Content

UsernamePublicRestriction

Register

MT024714

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel